Keywords
Abstract
This scientific study was carried out on 43 patients with chronic viral hepatitis C. Among the examined patients, there were 23 men (53,5%) and 20
women (46,5%). The age of the patients ranged from 18 to 59 years (the average age of patients was 36,2±5,36 years). The diagnostic significance of the APRI and AFP index in the progression of liver fibrosis to cirrhosis in patients with chronic viral hepatitis C was studied. According to laboratory studies, it was revealed that a significant increase in the value of an indirect marker of liver fibrosis - APRI (AST to platelet ratio index) was detected in patients with chronic viral hepatitis C in the presence of liver fibrosis at stage F1-F4 compared with patients with normal liver density - F0, at p <0,05. There was a twofold increase in the average marker of liver cell regeneration alpha-fetoprotein - AFP in patients with chronic viral hepatitis C in the presence of liver density F1-F4 compared with patients with normal liver density (F0) (p <0,05).
References
Bachofner J. A., Valli P. V., Kröger A. et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int., 2017. – N 37(3). – P. 369-376.
Bertino G., Ardiri A., Proiti M. et al. Chronic hepatitis C: This and the new era of treatment. World J. Hepatol, 2016. – N 8(2). – P. 92-106.
Boursier J. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standarts / J. of Hepatology, 2015. - № 62. - P. 807-815.
Deltenre P. Studies on the epidemiology of hepatitis B and C virus infections are still needed / J. of Hepatology. 2015. – № 62. - P. 1225-1227.
Ellis E. L. Clinical evidence for the regression of liver fibrosis / J. Hepatol. 2012. - V. 56. - № 5. - P. 1171-1180.
Ferenci P., Bernstein D., Lalezari J. et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV // N. Engl. J. Med., 2014. - Vol. 370. - N 21. - P. 1983-1992.
Lawitz E., Hezode C., Varunok P. et al. Interferon- and ribavirinfree regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-naive patients and prior null responders // Hepatology. 2013. - Vol. 58. - P. 244.
Li K. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates / Hepatology, 2012. - V. 55. -
№ 3. - Р. 666-675.
Simmons В., Saleem J., Heath K. Long-term treatment outcomes of patients infected with hepatitis С virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin. Infect. Dis., 2015. - Vol.
- N5. - Р. 730-740.
Sriphoosanaphan S., Thanapirom K., Suksawatamnuay S. et al. Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using directacting antiviral therapy. BMC Gastroenterol., 2020. – N 20(1). – P. 346.
The European Association for the Study of the Liver (EASL). Recommendations on treatment of hepatitis C. 2015. J of Hematology, 2015. - Vol. 63. - Р.199-236.
Tsiara C. G., Nikolopoulos G. K., Dimou N. L. et al. Effect of hepatitis C virus on immunological and virological responses in HIV-infected patients initiating highly active antiretroviral therapy: a meta-analysis / J Viral Hepat., 2013. – N
(10). – P. 715-724.
Wang Q. B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis / Hepatology, 2012. – V. 56. – № 1. - P. 239-247.
Wedemeyer H., Dore G. J., Ward J. W. Estimates on HCV disease burden worldwide – filling the gaps. J. Viral Hepat., 2015. - Vol. 22. - Suppl. 1. – Р. 1-5.
Wolffran I. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios / J. of Hepatology, 2015. - № 62. – Р. 1256-1264.